Despite significant advances in the prevention and treatment of heart failure (HF), the prognosis in patients who have been hospitalised on at least one occasion due to exacerbation of HF is still poor. Therefore, a better understanding of the underlying pathophysiological mechanisms of HF is crucial in order to achieve better results in the treatment of this clinical syndrome. One of the areas that, for years, has aroused the interest of researchers is the activation of the immune system and the elevated levels of biomarkers of inflammation in patients with both ischaemic and non-ischaemic HF. Additionally, it is intriguing that the level of circulating pro-inflammatory biomarkers correlates with the severity of the disease and prognosis in this group of patients. Unfortunately, clinical trials aimed at assessing interventions to modulate the inflammatory response in HF have been disappointing, and the modulation of the inflammatory response has had either no effect or even a negative effect on the HF prognosis. The article presents a summary of current knowledge on the role of immune system activation and inflammation in the pathogenesis of HF. Understanding the immunological mechanisms pathogenetically associated with left ventricular remodelling and progression of HF may open up new therapeutic possibilities for HF.

A new group of antidiabetic drugs, sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors), have recently been shown to have anticancer effects and their expression has been confirmed in many cancer cell lines. Given the metabolic reprogramming of these cells in a glucose-based model, the ability of SGLT-2 inhibitors to block the glucose uptake by cancer cells appears to be an attractive therapeutic approach. In addition to tumour cells, SGLT-2s are only found in the proximal tubules in the kidneys. Furthermore, as numerous clinical trials have shown, the use of SGLT-2 inhibitors is well-tolerated and safe in patients with diabetes and/or heart failure. In vitro cell culture studies and preclinical in vivo studies have confirmed that SGLT-2 inhibitors exhibit antiproliferative effects on certain types of cancer. However, the mechanisms of this action remain unclear. Even in those tumour cell types in which SGLT-2 is present, there is sometimes an SGLT-2-independent mechanism of anticancer action of this group of drugs. This article presents the current state of knowledge of the potential mechanisms of the anticancer action of SGLT-2 inhibitors and their possible future application in clinical oncology.

Diabetes is a key independent risk factor in the development of heart failure (HF) and a strong, adverse prognostic factor in HF patients. HF remains the primary cause of hospitalisation for diabetics and, as previous studies have shown, when HF occurs in these patients, intensive glycaemic control does not directly improve the prognosis. Recent clinical studies assessing a new class of antidiabetic drugs, sodium-glucose cotransporter 2 inhibitors (SGLT2is) showed some unexpected beneficial results. Patients treated with SGLT2is had a significant decrease in both cardiovascular (CV) and all-cause mortality and less hospitalisations due to HF compared to those given a placebo. These significant clinical benefits occurred quickly after the drugs were administered and were not solely due to improved glycaemic control. These groundbreaking clinical trials’ results have already changed clinical practice in the management of patients with diabetes at high CV risk. These trials have triggered numerous experimental studies aimed at explaining the mechanisms of action of this unique group of drugs. This article presents the current state of knowledge about the mechanisms of action of SGLT2is developed for the treatment of diabetes and which, thanks to their cardioprotective effects, may, in the future, become a treatment for patients with HF.

No abstract

This work contains an analysis of the impact of modifying a bioresorbable polymer—polycaprolactone (PCL)—with various additives on its antibacterial properties. To this end, samples of PCL filament containing various content levels of graphene (GNP), 0.5%, 5%, 10%, were obtained using injection molding. Polymer samples without additives were used for comparison. The next step was to assess the antimicrobial impact of the preparations under study against the following microorganisms: Staphylococcus aureus ATCC 25293, Escherichia coli ATCC 25922, Candida albicans ATCC 10231. Effective bactericidal activity of PCL with small amount of GNP, especially against C. albicans and S. aureus was confirmed. A decrease in this property or even multiplication of microorganisms was observed in direct proportion to the graphene content in the samples.

Purpose: Innovative biomedical filaments for 3D printing in the form of short and biodegradable composite sticks modified with various additives were used to prepare biomaterials for further nasal implants. As the respiratory tract is considered to be potentially exposed to contamination during the implantation procedure there is a need to modify the implant with an antibacterial additives. The purpose of this work was to analyze the effect of biodegradable polymer – polycaprolactone (PCL) modification with various additives on its antibacterial properties. Methods: PCL filament modified with graphene (0.5, 5, 10% wt.), bioglass (0.4% wt.) and zinc-doped bioglass (0.4% wt.) were used to print spatial biomaterials using FDM 3D printer. Pure polymer biomaterials without additives were used as reference samples. The key task was to assess the antimicrobial impact of the prepared biomaterials against the following microorganisms: Staphylococcus aureus ATCC 25293, Escherichia coli ATCC 25922, Candida albicans ATCC 10231. Results: The research results point to a significant antibacterial efficacy of the tested materials against S. aureus and C. albicans, which, however, seems to decrease with increasing graphene content in the filaments. A complete lack of antibacterial efficacy against E. coli was determined. Conclusions: The tested biomaterials have important antibacterial properties, especially against C. albicans. The obtained results showed that biomaterials made of modified filaments can be successfully used in implantology, where a need to create temporary tissue scaffolds occurs.

No abstract

BACKGROUND: Craniocerebral injuries belong to the category of bodily injuries which are characterised by high mortality and a high percentage of permanent effects in the form of disability. The likelihood of this injury exists in the workplace too. Performing works at a hight or using high-pressure or mechanical machinery exposes employees to a higher risk of a craniocerebral injury. CASE REPORT: This case study deals with the topic of open craniocerebral trauma suffered by a 20-year-old man who was wearing no head protection at his place of work. It details the management of this trauma at the site of the accident, during transfer to the hospital and during hospitalisation. CONCLUSION: Fast transport, effective diagnostics and implementation of surgical treatment contributed to a good final result.